Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta.

Clinical Pharmacology and Therapeutics
Gaby A M EliesenRick Greupink

Abstract

Tumor necrosis factor (TNF) inhibitors are increasingly applied during pregnancy without clear knowledge of the impact on placenta and fetus. We assessed placental transfer and exposure to infliximab (n = 3) and etanercept (n = 3) in women with autoimmune diseases. Furthermore, we perfused healthy term placentas for 6 hours with 100 µg/mL infliximab (n = 4) or etanercept (n = 5). In pregnant women, infliximab transferred into cord blood but also entered the placenta (cord-to-maternal ratio of 1.6 ± 0.4, placenta-to-maternal ratio of 0.3 ± 0.1, n = 3). For etanercept, a cord-to-maternal ratio of 0.04 and placenta-to-maternal ratio of 0.03 was observed in one patient only. In ex vivo placenta perfusions, the extent of placental transfer did not differ between the drugs. Final concentrations in the fetal compartment for infliximab and etanercept were 0.3 ± 0.3 and 0.2 ± 0.2 µg/mL, respectively. However, in placental tissue, infliximab levels exceeded those of etanercept (19 ± 6 vs. 1 ± 3 µg/g, P < 0.001). In conclusion, tissue exposure to infliximab is higher than that of etanercept both in vivo as well as in ex vivo perfused placentas. However, initial placental transfer, as observed ex vivo, does not differ between infliximab an...Continue Reading

References

Jan 1, 1994·Placenta·G BarkerC P Sibley
Aug 19, 2007·Nature Reviews. Immunology·Derry C Roopenian, Shreeram Akilesh
Jan 26, 2010·Reproductive Toxicology·Line MathiesenLisbeth Ehlert Knudsen
Dec 20, 2013·Rheumatology·Kimme L Hyrich, Suzanne M M Verstappen
Jan 31, 2015·Journal of Perinatology : Official Journal of the California Perinatal Association·L GlasserJ T Machan
Mar 27, 2015·British Journal of Clinical Pharmacology·Corinna Weber-SchoendorferChristof Schaefer
Apr 3, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xi ChenWilliam J Jusko
Oct 8, 2015·Inflammatory Bowel Diseases·Ryan A McConnell, Uma Mahadevan
Feb 19, 2016·Annals of the Rheumatic Diseases·Carina Götestam SkorpenMonika Østensen
Apr 10, 2017·Rheumatic Diseases Clinics of North America·Pascal H P de Jong, Radboud J E M Dolhain
Jul 12, 2017·Therapeutic Drug Monitoring·Ji S van BezooijenTeun van Gelder
Mar 15, 2018·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Giuseppe ChiossiGiovanni B La Sala
May 18, 2018·Journal of Crohn's & Colitis·Shannon L KanisC Janneke van der Woude
May 29, 2018·Annals of Clinical Biochemistry·J G Sanchez-HernandezM V Calvo
Jul 5, 2018·Expert Review of Gastroenterology & Hepatology·Jantien W WieringaC Janneke Van Der Woude

❮ Previous
Next ❯

Citations

Apr 30, 2021·Frontiers in Immunology·Panagiotis F ChristopoulosEirik Sundlisæter
Jul 28, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Carla CarnovaleIrene Cetin

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
biopsies

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Kevin L Winthrop, Jeffrey N Siegel
© 2021 Meta ULC. All rights reserved